Minimal residual disease in plasma cell (multiple) myeloma: flow cytometric approaches
The minimum residual disease (MRD) for hematopoietic and lymphoid systems tumors is an important component of patient examination during therapy. The MRD detection is performed to evaluate the effect of therapy and risk stratification during chemotherapy (acute leukemia) or at the end of it (periphe...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2020-04-01
|
Series: | Onkogematologiâ |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/404 |